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Metastasis is a leading cause of poor prognosis and cancer deathworldwide and according to reports,
metastasis results in almost 90% cancer-related deaths (1). The early detection of cancer and better
understanding of cancer metastasis can be incredibly helpful in management of disease (2).
Recently, there is a great advancement in metastasis-related research but yet prognosis remains
extremely poor. Metastasis is a very complex process, which is mainly through four steps: (i)
departure of cells from the primary tumor, (ii)movement and survival of cancerous cells in circulator
system, (iii) attachment of cells with the target organ through breaching of endothelial and basement
membrane, and (iv) formation of metastatic cells colony in target organ (3). There are many
players who are involved in these steps including nervous system,microenvironment, inflammation,
immune system, and bonemarrow (4–6). Among all these factors, nervous and immune system play
an important role, directly or indirectly (7).
Angiogenesis is very important for metastasis (8) and for angiogenesis; vascular endothelial
growth factor (VEGF) plays an important role. According to the reports, the level of VEGF increases
in chronic stress, which result in vascularization and lead to metastasis (9, 10). In addition, under
chronic stress, the sympathetic nervous system (SNS) also activated, which release neurotransmitters
and these neurotransmitters, such as norephedrine, dopamine, and bradykinin, induce or suppress
VEGF expression (11, 12).
Other neuron-related factors also play an important role in tumor angiogenesis like neuropilins
and semaphorins. These factors can promote or inhibit the angiogenesis process (13–15). Moreover,
calcitonin gene-related peptide (CGRP), which is a neuropeptide, can also facilitate angiogenesis
in tumor (16). Another neuropeptide, neuropeptide Y (NPY), is also involved in angiogenesis by
regulating the expression of VEGF (17). Overall, nervous system modulates angiogenesis, which
further lead to metastasis.
According to a recent study by Magnon et al. (18), tumor sections of mouse contained tumor
infiltrating sympathetic and parasympathetic nerves and along with mature there were also some
newly formed nerves. In the same study, when sympathetic nerve were ablated surgically or
chemically, the growth of tumor was prevented in mice and similar results were also obtained when
same nerve were ablated in genetic model of prostate cancer. In the later case, only cancer was
prevented in young mice but no effect was observed in adults, which indicate that SNS is important
for early tumorigenesis (18). Themechanism of tumor growth by SNSwas also revealed in this study
and that was through β2-adrenergic receptor (ADRB2). ADRB2 has been shown to be expressed on
tumor cells, while SNS transmits stress signals, which activate these receptors and result in tumor
growth.
Some recent investigations have challenged the canonical theory of tumor metastasis and accord-
ing to new theory, the cancerous cells have an innate property of metastasis and malignant cells can
disseminate and release into circulation much earlier than previously anticipated (19). In addition,
the non-neoplastic host cells in tumor microenvironment including neuronal cells also play a
significant role in regulation of metastasis (18).
Metastasis is always said to be a bad process and usually it is considered as “death statement”
for patient but can it be beneficial? According to a study by Peeters et al. (20), primary tumor may
inhibit the growth of metastasized tumor, as the vascular density in human liver metastatic cancer
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increased after primary tumor resection from colon (20). Accord-
ing to this study, primary tumor blocks the growth ofmetastasized
tumor by blocking angiogenesis process. In this way, the stress at
primary tumor place is reduced by release of cells and primary
tumor further helps in blocking the growth of metastatic tumor.
There are several cases where there was spontaneous regression
of primary tumors and especially renal cell carcinoma (RCC).
Like metastasis, the process of regression is also very complex
and many genetics, epigenetic, immunological, and neurological
factors are involved, which act through apoptosis, immune system
activation, tumor microenvironment, inhibition of metallopro-
teinases, lack of angiogenesis, and absence of specific proteins.
All these factors act together and result in tumor regression (21,
22). In addition, there are also several documented cases of spon-
taneous regression of metastatic tumor, but what mechanism is
involved in this regression is still unknown and needs further
investigations (23–25).
According to different reports, all type of tumors can regress
spontaneously, although, some cancers regress more frequently
than others. In addition, not only malignant but regression was
also observed in benign tumors [Sante Basso (26)]. Moreover, the
dilution in numbers of cancer cells in the blood also stimulates
the immune system and result in regression. It was observed
that metastasis was less frequent in renal carcinoma patients who
undergo hemodialysis, which indicates that, the number of cancer
cells reduced due to their blockage using dialytic membrane. Can-
cer cells are slowly released in circulation from primary tumor,
so more accessible to immune cells; and hence, immune system
recognize these cells in better way and prepare the body to fight
against cancer, which could be hard in primary solid tumor [S
Basso (27); Sante Basso (26)].
The primary tumor normally escape the anti-tumor response
of the immune system and many factors play an important role
for this escape, especially tumor microenvironment and immune
system exclusion and ignorance (28, 29). It indicates that the
access of immune cells to primary tumor is less. In addition, if
the patient are administered with autologous cancer cells, they
enhance the anti-tumor immunity in patients, especially when the
cells were engineered to secrete granulocyte-macrophage colony
stimulating factor (GM-CSF), which indicate that circulating can-
cer cells are better recognized by immune cells and they mount
anti-tumor response (30, 31), so metastasis make the tumor cells
more accessible to immune cells.
According to reports, the process of regression ismore common
in metastasized tumor compared to primary tumors [Sante Basso
(26)]. When cancer cells move to new location, the microenvi-
ronment at new location also affect the cancer cells and block
its proliferation. In addition, microenvironment also lock the
cancer cells, which reduce their number in circulation and so
help in mounting the immune response due to dilution factor of
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FIGURE 1 | A simple model to illustrate that how metastasis is helpful
for the body.
cancerous cells. The cells releases from primary tumor are also not
always form a tumor at new location. Moreover, after release from
the primary tumor, certain tumor cells end up into lymph nodes,
which are highly active sites of immune system, so these cancer
cells are not only blocked but also greatly stimulate the immune
system, which result in spontaneous regression of cancer. Several
such cases of spontaneous regression of lymph node metastasis
have been reported (32). Howmetastasis is beneficial for the body
is simply illustrated in Figure 1.
On the basis of above discussion, it can be concluded that
although metastasis is not good for treatment of cancer, as it is
hard to treat cancer when it is not localized but there is also need
to re-think about metastasis process, as it is a body’s response to
target the diseases andmount an immune response against cancer-
ous cells. The nervous system modulate and facilitate metastasis
to reduce the stress of cancer mass at its primary location and
better expose cancer cells, so the immune system could recognize
them and target these cells not only at its primary location but
also at metastatic locations. Just like the old theory of release of
cancer cells from primary tumor is changed, we have to re-think
about metastatic process as metastasis is also helpful for the body
in number of ways (Figure 1). The new theory can also give us
many potential new targets and ways to target cancer.
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